AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02315131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV46017
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
Study NCT01432470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
Study NCT02315131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02044913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based Aftercare-Coordination
Description: After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
Study NCT00765063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin
Description: Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
Study NCT00988949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04455242
Description: Single oral 18 mg dose of PF-04455242.
Study NCT01735435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry
Description: The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes.
Study NCT03528447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band.
Study NCT04222400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Frailty Assessment
Description: Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
Study NCT01432470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
Study NCT01579994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) and crizotinib
Description: Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
Study NCT04606862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morley Medical Sepsis Software Device
Description: The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
Study NCT01753765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Cryo-Touch III Study treatment at Day 0.
Description: Device: Cryo-Touch III Study treatment at Day 0.
Study NCT03159052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 52 weeks
Study NCT03159052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily, 24 weeks
Study NCT02073292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: c-RFA
Study NCT02073292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tRFA
Study NCT03547674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: barefoot
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
Study NCT03547674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shoes only
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
Study NCT03547674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: untuned AFO with shoes
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
Study NCT03547674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tuned AFO with shoes
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
Study NCT04185766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Administration of a placebo solution (0.5 ml / kg)
Description: 43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
Study NCT04185766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Administration of a placebo solution (1 ml / kg)
Description: 43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
Study NCT04185766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of 40% glucose in gel (0.5 ml / Kg)
Description: 43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
Study NCT04185766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of 40% glucose in gel 1 ml / Kg)
Description: 43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
Study NCT00988949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spiradoline
Description: Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
Study NCT04018716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MTA
Description: Indirect capping with MTA
Study NCT04018716 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dycal
Description: Indirect capping with Dycal
Study NCT03400202 — intervention group
Intervention type: DEVICE
Intervention: Skin imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
Study NCT03839966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification for Loneliness
Description: Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard \& Amir, 2008 and Beard, Weisberg, \& Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
Study NCT03839966 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Habits Psychoeducation and Relaxation
Description: Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
Study NCT01660425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancement with psychosocial intervention
Study NCT03613233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma surgery
Description: phacoemulsification
Study NCT03352739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the fornix, power on
Description: DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead
Study NCT03352739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the NbM, power on
Description: DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead
Study NCT03352739 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS of the fornix, power off
Description: DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead
Study NCT03352739 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS of the NbM, power off
Description: DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead
Study NCT01994785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnographic Monitoring
Description: Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
Study NCT03251001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
Study NCT03251001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
Study NCT06489210 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: popliteal block
Description: using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
Study NCT03700502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional Magnetic Resonance Imaging
Description: The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
Study NCT02351661 — intervention group
Intervention type: OTHER
Intervention: There was no intervention
Description: observational study, no intervention
Study NCT04834609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of autologous adipose tissue in anal fistula
Study NCT04012567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device: Biosure Regenesorb Interference Screw
Description: The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.
Study NCT04012567 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control device: BIOSURE HA Interference Screw
Description: BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
Study NCT01694225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bubble packaging for monthly prescription
Description: Monthly bubble packaging among women prescribed anti-estrogens
Study NCT00988949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo.
Study NCT00988949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spiradoline
Description: Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
Study NCT00988949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04455242
Description: Single 30 mg oral dose of PF-04455242.
Study NCT00966212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parent education
Description: Especially for Daughters audio-cd parent education
Study NCT04347382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honey
Description: 1gm/Kg/Day
Study NCT04347382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa / Black Cumin
Description: 80mg/Kg/day
Study NCT01034774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACHN-490 Injection
Description: ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
Study NCT01034774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
Study NCT00209053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass
Study NCT00209053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass
Study NCT01846078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical biometric measurement (IOLMaster)
Description: IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
Study NCT03042143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord derived CD362 enriched MSCs
Description: Infusion of Human umbilical cord derived CD362 enriched MSCs
Study NCT03042143 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Plasma-Lyte 148)
Description: Infusion of placebo
Study NCT03749278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Latina Friends Motivating the Soul (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
Study NCT03749278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Latina Friends Motivating the Soul (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
Study NCT02108314 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Screening and Counselling
Description: The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
Study NCT01755455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
Study NCT01755455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule
Study NCT02744196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellbia
Description: Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
Study NCT02744196 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Acellbia
Description: Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
Study NCT02744196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will look identical to the Acellbia solution.
Study NCT02744196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT01207453 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Milnacipran
Description: Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
Study NCT01207453 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT04093050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasostrict Injectable Product
Description: Vasostrict® (vasopressin injection, USP)
Study NCT01334606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 mm x 32G pen needle (Nano)
Description: The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
Study NCT01334606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8mm x 31G pen needle (Short)
Description: The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
Study NCT04806659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH1573 Capsules
Description: Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Study NCT03376763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify maintena
Description: Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
Study NCT02735005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMAF assessment
Description: After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)
Study NCT02452567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate (8-10%) diet-induced weight loss
Description: MAL participants will meet with the study dietitian to lose \~8-10% of their body weight through diet-intervention.
Study NCT00193050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT00193050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin